BioSig Technologies Completes Public Offering
BioSig Technologies, Inc. (NASDAQ: BSGM) has reached a significant milestone by successfully closing a $15 million public offering. This event marks an exciting chapter in the company's journey, particularly following its recent merger with Streamex Exchange Corporation, which specializes in gold tokenization infrastructure.
Details of the Offering
The offering included 3,852,149 shares of common stock, priced at $3.90 per share without any pre-funded warrants. The gross proceeds amount to approximately $15,023,381 before deductions for underwriter discounts, commissions, and associated expenses. This capital influx is expected to facilitate BioSig's strategic initiatives.
Planned Use of Proceeds
BioSig intends to utilize the net proceeds from this offering primarily to acquire gold bullion, aligning with the company’s investment policy. Additionally, the funds will support general corporate purposes and enhance working capital, reinforcing the company's operational capabilities.
Leadership Insights
Henry McPhie, the CEO of BioSig and Co-Founder of Streamex, expressed optimism regarding the merger and public offering. He stated, "We have successfully combined a short and long-term capital strategy that attracts quality investors. This financial support is pivotal as we aim to solidify our position in the gold bullion and real-world asset markets while enhancing shareholder value."
Involvement of Joint Book-Running Managers
The success of this offering is partly due to the joint efforts of Clear Street and Needham & Company, who acted as book-running managers. Their industry expertise played a crucial role in the execution of this offering.
Regulatory Compliance
This offering was conducted following a shelf registration statement on Form S-3, which received approval from the Securities and Exchange Commission (SEC). This registration allows companies to issue securities over a period without repeated disclosures, making it a flexible option for capital raising.
About Streamex
Streamex, a subsidiary under BioSig Technologies, focuses on creating institutional-grade infrastructure designed to simplify access to the gold market via blockchain technologies. Their innovative approach aims to enhance the robustness and accessibility of the financial systems surrounding gold investments.
About BioSig Technologies
BioSig Technologies stands at the forefront of medical device technology with its advanced digital signal processing technology platform, the PURE EP™ Platform. This state-of-the-art system provides electrophysiologists with critical insights necessary for effective cardiac arrhythmia treatments.
The Importance of Pure EP™ Platform
The PURE EP™ Platform's capabilities allow for the real-time acquisition of raw electrophysiological signal data while minimizing noise and interference. This precision is vital for maximizing the success of ablation procedures and enhancing overall patient outcomes.
Looking Ahead
With the recent fundraising, BioSig is well-positioned to drive its growth strategy forward. The integration of Streamex technologies into their operations is expected to create substantial opportunities within both the medical technology and gold markets.
Frequently Asked Questions
What is BioSig Technologies, Inc.?
BioSig Technologies, Inc. is a medical device company that utilizes advanced digital signal processing for cardiac arrhythmia treatments.
What was the outcome of the recent public offering?
BioSig closed a public offering bringing in approximately $15 million to support its operational and corporate strategies.
How will the proceeds from the offering be used?
The proceeds will primarily be used for purchasing gold bullion, general corporate purposes, and enhancing working capital.
What is the PURE EP™ Platform?
The PURE EP™ Platform is a digital signal processing technology designed to provide electrophysiologists with enhanced insights for cardiac procedures.
Who are the book-running managers for the offering?
Clear Street and Needham & Company acted as joint book-running managers for the public offering.
